Table 2. Age-related anti-EBV antibodies in all non-nasopharyngeal carcinoma patients visiting the PUMC Hospital, Beijing, 2013–2017.
| VCA IgG Pos no. (%) |
VCA IgM Pos no. (%) |
VCA IgA Pos no. (%) |
EA/D IgA Pos no. (%) |
EBNA1 IgG Pos no. (%) |
|
|---|---|---|---|---|---|
| 0–5y | 283(66.59) | 65(14.57) | 52(14.57) | 26(7.12) | 141(58.51) |
| 6–10y | 429(84.28) | 55(10.28) | 92(22.66) | 39(9.20) | 226(78.75) |
| 11–20y | 775(92.81) | 123(10.49) | 171(23.05) | 89(11.54) | 411(86.89) |
| 21–30y | 774(98.47) | 88(6.40) | 160(22.79) | 96(12.80) | 268(94.37) |
| 31–40y | 811(98.78) | 39(3.07) | 182(19.72) | 97(9.67) | 199(94.76) |
| 41–50y | 759(99.74) | 35(2.98) | 170(15.15) | 109(9.24) | 189(97.42) |
| 51–60y | 822(99.76) | 31(2.43) | 185(19.33) | 108(10.44) | 238(95.97) |
| 61–101y | 834(98.93) | 24(1.77) | 202(28.53) | 101(13.93) | 252(93.68) |
| Male | 2613(93.62) | 222(5.3) | 608(19.70) | 343(10.57) | 911(86.60) |
| Female | 2874(95.39) | 238(5.37) | 606(21.41) | 322(10.71) | 1013(87.78) |
| Total | 5487(94.54) | 460(5.36) | 1214(20.52) | 665(10.64) | 1924(87.22) |